Just As I Said It Would -- UK Single-Payer Now Covers Pembrolizumab For Lung -- After Sharper Pencil Price Negotiations

I won't unduly belabor the point, but this is increasingly the new multi-national model for new drug pricing (Keytruda^® pricing being a rather pointed example): often rather steep discounts from US list prices.

Even as to truly revolutionary treatments, the world's governmental-affiliated payers will increasingly seek -- and win -- price concessions from big pharma. And Mr. Frazier is (smartly, I think, given the incoming Administration is also likely to target drug pricing) talking peace, on price increases, more generally.

Here is the overnight item -- you may read it for yourself. But it was all easily predictable, back from June to October 2016.

Onward.

नमस्ते